Valle-Solís AE, Miranda-Aguirre AP, Mora-Pérez J, Pineda-Juárez JA, Gallardo-Valencia LE, Santana L, Cervantes-Sanchez G, Cárdenas-Cárdenas E

Language: Spanish
References: 21
Page: 50-55
PDF size: 155.03 Kb.

ABSTRACT

Background: Breast cancer subtype classification according to hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) using immunohistochemistry is the standard practice for therapeutic decision making. Objective: To design future studies information on characteristics and survival of each subtype is essential. Method: We conducted a retrospective study to analyze clinical and pathologic features as well as survival data according to breast cancer immunohistochemistry subtype. Results: There were 211 women with a RH(+)/HER2(–) breast cancer subtype, 53 HR(+)/HER2(+), 16 HER2(+) and 23 HR(–)/HER2(–), with a median overall survival in months of 39 (20.5-62.7), 42 (25.5-65), 42 (13.7-67.7) and 26 (11-78), respectively, for a 3.7 hazard ratio of death (95% Confidence Interval [CI]: 1.3-10.3) for the triple negative group as compared to the HR(+)/HER2(–) group (p = 0.01). Conclusions: HR positive subtypes by immunohistochemistry where most frequent and showed a greater overall survival compared to the triple negative subtype.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.

2. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: Epidemiology and etiology. Cell Biochem Biophys. 2015;72:333-8.

3. Rodríguez Cuevas S, Capurso García M. Epidemiología del cáncer de mama. Ginecol Obstet Mex. 2006;74:585-93.

4. Estadísticas vitales. Defunciones generales y fetales [Internet]. México: INEGI 2016. Disponible en: http //www3.inegi.org.mx/rnm/index.php/catalog/ 303

5. Aldaco-Sarvide F, Pérez-Pérez P, Cervantes-Sánchez G, Torrecillas-Torres L, Argentina Erazo-Valle-Solís A, Cabrera P, et al. Mortalidad por cáncer en México: actualización 2015. Gac Mex Oncol. 2008;17:28-34.

6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.

7. Wishart GC, Bajdik CD, Azzato EM, Dicks E, Greenberg DC, Rashbass J, et al. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol. 2011;37:411-7.

8. Schmidt S, Monk JM, Robinson LE, Mourtzakis M. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise. Obes Rev. 2015;16:473-87.

9. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-502.

10. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2:444-55.

11. Rakha EA, El-Sayed ME, Reis-Filho JS, Ellis IO. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology. 2008;52:67-81.

12. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206-23.

13. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012;21:50-7.

14. Engstrom MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat. 2013;140:463-73.

15. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4-13.

16. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population- based study from the South of Switzerland. Ann Oncol. 2009; 20;628-35.

17. Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/ HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;2014:11.

18. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279.

19. Incorvati JA, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol. 2013;6:38.

20. Reynoso-Noverón N, Villarreal-Garza C, Soto-Perez-de-Celis E, Arce- Salinas C, Matus-Santos J, Ramírez-Ugalde MT, et al. Clinical and epidemiological profile of breast cancer in Mexico: Results of the Seguro Popular. J Glob Oncol. 2017;3:757-64.

21. Pérez-Rodríguez G. [Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social]. Cir Ciruj. 2015;83:193-8.